



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *C07K 16/32* (2006.01)
- (21) **International Application Number:**
PCT/NL2015/050124
- (22) **International Filing Date:**
27 February 2015 (27.02.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
14157351.9 28 February 2014 (28.02.2014) EP
- (71) **Applicant:** MERUS B.V. [NL/NL]; Padualaan 8 (postvak 133), NL-3584 CH Utrecht (NL).
- (72) **Inventors:** LOGTENBERG, Ton; c/o Padualaan 8 (postvak 133), NL-3584 CH Utrecht (NL). THROSBY, Mark; c/o Padualaan 8 (postvak 133), NL-3584 CH Utrecht (NL). ROOVERS, Robertus Cornelis; c/o Padualaan 8 (postvak 133), NL-3584 CH Utrecht (NL).
- (74) **Agent:** JANSEN, C.M.; V.O., Johan de Wittlaan 7, NL-2517 JR Den Haag (NL).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** ANTIBODIES THAT BIND EGFR AND ERBB3

(57) **Abstract:** The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC₅₀) of less than 200 p M for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.

